ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients. (PubMed, Bone Marrow Transplant) - May 7, 2025 - "Clinical risk factors (e.g., early CMV infection, acute graft-versus-host disease) predicted late csCMV and improved the predictive value of CMV-CMI testing. Thus, standardized CMV-CMI, after HCT, combined with clinical factors can be used to accurately stratify the risk of late csCMV infection after letermovir prophylaxis."
Journal • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Alicja Sadowska-Klasa; Andrea Vivas-Jimenez; Clarissa Santiano; Danniel Zamora; Eleftheria Kampouri; Elizabeth Wong; Hu Xie; Joshua A Hill; Masumi Ueda Oshima; Michael Boeckh; Terry Stevens-Ayers; Wendy M Leisenring
|